When aripiprazole (ABILIFY) received its approval in Germany for the treatment of schizophrenia, a hospital-based postmarketing surveillance study was initiated in order to gain further insights concerning safety and efficacy of the antipsychotic under real-life conditions. Efficacy was rated by using standard CGI, GAF, and SF-12 instruments, whereas safety was evaluated according to the reports on adverse effects. Data from 799 patients with schizophrenia from 122 psychiatric hospitals returned for evaluation. Eighty percent of the patients were treated for 4 weeks with 10-30 mg/day aripiprazole (mean modal dose 15 mg/day). Within the observation period significant improvements of CGI, GAF, and SF-12 ratings was observed. Aripiprazole was tolerated well by the patients. Most frequent adverse effects were insomnia, irritability, restlessness, nausea and vomiting, in general being moderate to mild and corresponding to the known tolerability profile of aripiprazole. The results demonstrate that the administration of aripiprazole can result in an improvement of the symptoms of schizophrenia within 4 weeks in a real-life hospital-based in- and outpatient setting.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/15622970701429854 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Objective: Aim: To investigate the etiology, pathogenesis, and effectiveness of pharmacotherapy and psychotherapeutic modalities of delusions in Schizophrenia spectrum and other Psychotic Disorders.
Patients And Methods: Materials and Methods: In our study, we included English-language studies from online databases such as Web of Science, Scopus, Google Scholar, PubMed, and the Cochrane Library conducted until January 2024 using the following keywords "delusions", "Schizophrenia spectrum and other Psychotic Disorders", "pharmacotherapy", "psychotherapy", and "antipsychotics". Scientific novelty: There is already published evidence that has studied Schizophrenia spectrum disorders from definition to treatment.
Neuroinflammation mediates the progression of neonate hypoxia-ischemia brain damage to Alzheimer's disease: a bioinformatics and experimental study.
Front Aging Neurosci
January 2025
School of Medicine, Yunnan University, Kunming, China.
Background: Traumatic brain injury (TBI) can generally be divided into focal damage and diffuse damage, and neonate Hypoxia-Ischemia Brain Damage (nHIBD) is one of the causes of diffuse damage. Patients with nHIBD are at an increased risk of developing Alzheimer's disease (AD). However, the shared pathogenesis of patients affected with both neurological disorders has not been fully elucidated.
View Article and Find Full Text PDFA Cross-sectional Study of the Length of Stay of Persons with Mental Illnesses and Revenue to a Government Tertiary Neuropsychiatric Hospital Under Ayushman Bharat.
Indian J Psychol Med
January 2025
Psychiatric Rehabilitation Services, Dept. of Psychiatry, Bengaluru, Karnataka, India.
Background: Ayushman Bharat Pradhan Mantri Jan Arogya Yojana (AB-PMJAY) is a health insurance scheme launched by the Government of India (GOI) in 2018 to cover the in-patient (IP) treatment expenditures, including mental illness treatment expenditures, for 500 million Indians. AB-PMJAY pays 100% of treatment expenditures for persons below the poverty line (BPL) and 30% for people above the poverty line (APL). Ayushman Bharat Arogya Karnataka (ABAK) trust implements this scheme in Karnataka, a southern Indian state.
View Article and Find Full Text PDFA review of clinical applications of pharmacokinetic simulations for a 2-month long-acting injectable formulation of aripiprazole.
Curr Med Res Opin
January 2025
Otsuka Pharmaceutical Development & Commercialization Inc., Princeton, NJ, USA.
Aripiprazole 2-month ready-to-use (Ari 2MRTU) is a long-acting injectable antipsychotic that was approved for use in Europe in March 2024, for the maintenance treatment of schizophrenia in adult patients stabilized with aripiprazole; it is administered via gluteal intramuscular injection once every two months. This review examines population pharmacokinetic model-based simulations relevant to the use of Ari 2MRTU in Europe, accompanied by expert commentary that contextualizes the simulations and highlights the potential implications of the availability of Ari 2MRTU for patients, caregivers, and clinicians. Various simulations conducted across 8 weeks (representing the first dosing interval), or 32 weeks (representing maintenance dosing) demonstrated an aripiprazole exposure profile for Ari 2MRTU that was similar to aripiprazole once-monthly (AOM), but with an extended dosing interval.
View Article and Find Full Text PDFAdvancements in Managing Schizophrenia through Classical Approaches, Mechanisms, and Deep Brain Stimulation.
Curr Pharm Des
January 2025
University Institute of Pharma Sciences (UIPS), Chandigarh University, NH-95 Chandigarh Ludhiana Highway, Mohali Punjab, India.
Schizophrenia is a heterogeneous neuropsychological disorder characterized by three distinct sets of symptoms: positive, negative, and cognitive. It carries significant public health implications and is estimated to affect up to 1% of the population. Despite extensive research, the underlying mechanisms of schizophrenia are not entirely understood, and existing antipsychotic treatments have notable limitations.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!